Serum N-Terminal Brain Natriuretic Peptide Indicates Exercise Induced Augmentation of Pulmonary Artery Pressure in Patients with Mitral Stenosis

Kılıçkesmez, Kadriye Orta; Arat-Özkan, Alev; Abacı, Okay; Çamlıca, Hakan; Kocas, Cuneyt; Kaya, Ayşem; Başkurt, Murat; Yiğit, Zerrin; Küçükoğlu, Serdar

doi:10.1111/j.1540-8175.2010.01273.x

Cited by 9 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, it was seen in patients who were assessed through exercise tests that these levels correlated with left atrial diameter after resting and exercise, right ventricular enddiastolic diameter, exercise duration, heart rate and pulmonary artery pressure. Again in this study, NT-proBNP level >251 pg/ ml was an indicator of pulmonary artery pressure increasement with exercise above 60 mmHg (266).…”

Section: Mitral Stenosissupporting

confidence: 49%

Natriuretic Peptides in Clinical Practice

Çavuşoğlu

Alper²,

Altay³

et al. 2019

Anatol J Cardiol

View full text Add to dashboard Cite

Natriuretic peptides (NP) are commonly used diagnostic biomarkers in heart failure (HF). While the American HF guideline strongly recommends NPs as class I indication with the level of evidence A in the diagnosis of both acute and chronic HF (1), the European HF guideline recommends them as class I indicationwith the level of evidence A for acute HF and as class IIa indication with the level of evidence C for chronic HF (2). Similarly, NPs have been proven to be strong biomarkers for prognosis and risk assessment in HF. The American HF guideline recommends NPs as class I indication with the level of evidence A in the assessment of prognosis of both acute and chronic HF (1). Moreover, the American HF guideline recommends NP monitorization as class IIa indication with the level of evidence B for achieving optimal treatment target in chronic HF (1). However, it Natriuretic peptides have long been introduced into clinical practice. These biomarkers have certainly been shown to provide useful information in the diagnosis, prognosis and risk stratification in heart failure and also may have a role in the guidance of heart failure therapy. Although, there are some limitations in using of these markers such as lack of specificity, aging, renal dysfunction or obesity, among the huge number of candidates for heart failure biomarkers, only natriuretic peptides are currently widely used in daily clinical practice in heart failure. Recent heart failure guidelines recognize natriuretic peptides as an essential tool in the new diagnostic and therapeutic algorithms. Furthermore, natriuretic peptides are not only used in the diagnosis or prognosis of heart failure, but also these biomarkers are referred to have some potential role in primary prevention, cardio-oncology, advanced heart failure, assessment of response to cardiac resynchronization therapy, pulmonary arterial hypertension, acute coronary syndromes, atrial fibrillation and valvular heart disease. In this article, natriuretic peptides have been reviewed for their updated information and new recommendations in heart failure and also potential role of these biomarkers in the management of various clinical conditions have been addressed in the form of expert opinion based on the available data in the literature.

show abstract

Section: Mitral Stenosissupporting

confidence: 49%

Natriuretic Peptides in Clinical Practice

Çavuşoğlu

Alper²,

Altay³

et al. 2019

Anatol J Cardiol

View full text Add to dashboard Cite

show abstract

“…35 Moreover, NT-proBNP was the most important independent predictor of all-cause mortality in heart failure patients with atrial fibrillation, 36 and BNP is related to the extent of myocardial ischemia, 37 transvalvular gradient or valve area in patients with aortic stenosis, 25,38 amyloidosis, restrictive cardiomyopathy, and diastolic LV dysfunction, [39][40][41][42] right heart volume and pressure overload. 43,44 BNP is elevated in noncardiac diseases, such as pulmonary hypertension, chronic obstructive pulmonary disease, pulmonary embolism, renal failure, and sepsis. 45 Patients in our study were in sinus rhythm and did not have serious noncardiac disease history, symptoms or signs of ischemic heart disease, aortic stenosis, or other heart diseases.…”

Section: Discussionmentioning

confidence: 99%

“…Elevated plasma NT‐proBNP concentrations have been demonstrated in patients with syndrome X complicated by left bundle branch block with preserved systolic function 35 . Moreover, NT‐proBNP was the most important independent predictor of all‐cause mortality in heart failure patients with atrial fibrillation, 36 and BNP is related to the extent of myocardial ischemia, 37 transvalvular gradient or valve area in patients with aortic stenosis, 25,38 amyloidosis, restrictive cardiomyopathy, and diastolic LV dysfunction, 39–42 right heart volume and pressure overload 43,44 . BNP is elevated in noncardiac diseases, such as pulmonary hypertension, chronic obstructive pulmonary disease, pulmonary embolism, renal failure, and sepsis 45 .…”

Section: Discussionmentioning

confidence: 99%

Strain Value in the Assessment of Left Ventricular Function and Prediction of Heart Failure Markers in Aortic Regurgitation

et al. 2011

View full text Add to dashboard Cite

show abstract

“…When levels of BNP or NT–pro-BNP were compared in patients with sinus rhythm or atrial fibrillation (AF), the results were controversial 28 . Studies show a correlation between higher levels of NT‑pro‑BNP with greater increases in PASP after exercise, and a direct association between decreases in NT‑pro‑BNP levels after percutaneous mitral commissurotomy and the success rate of the procedure 29 , 30 Data collected from patients who underwent interventional procedures have demonstrated a decrease in BNP and NT‑pro‑BNP after percutaneous mitral valvuloplasty in patients in sinus rhythm, but not in those with AF.…”

Section: Biomarkers In Valvular Diseasementioning

confidence: 99%

Biomarkers in Cardiology - Part 2: In Coronary Heart Disease, Valve Disease and Special Situations

2015

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

Cardiovascular diseases are the main causes of mortality and morbidity in Brazil. Their primary and secondary preventions are a priority for the health system and require multiple approaches for increased effectiveness. Biomarkers are tools used to identify with greater accuracy high-risk individuals, establish a faster diagnosis, guide treatment, and determine prognosis. This review aims to highlight the importance of biomarkers in clinical cardiology practice and raise relevant points regarding their application and perspectives for the next few years. This document was divided into two parts. This second part addresses the application of biomarkers in coronary heart disease, valvular diseases, cardio-oncology, pulmonary embolism, and cardiorenal syndrome.

show abstract

Serum N-Terminal Brain Natriuretic Peptide Indicates Exercise Induced Augmentation of Pulmonary Artery Pressure in Patients with Mitral Stenosis

Abstract: NT pro-BNP levels correlate with functional class and echocardiographic findings in patients with mitral stenosis and indicate exercise induced augmentation of peak PAP > 60 mmHg. (Echocardiography 2011;28:8-14).

Cited by 9 publications

References 36 publications

Natriuretic Peptides in Clinical Practice

Natriuretic Peptides in Clinical Practice

Strain Value in the Assessment of Left Ventricular Function and Prediction of Heart Failure Markers in Aortic Regurgitation

Biomarkers in Cardiology - Part 2: In Coronary Heart Disease, Valve Disease and Special Situations

Contact Info

Product

Resources

About